News & Events

News Releases


Year: 2008 |2007 |2006 |2005 | 2004 | 2003

Nov 01, 2006

Aspreva Pharmaceuticals Reports Third Quarter 2006 Results and Updates Guidance

Oct 26, 2006

Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis

Oct 13, 2006

Aspreva Announces Preliminary Revenues for Third Quarter 2006

Oct 11, 2006

Aspreva Reports Analysis of Independent Investigator Initiated Trial of CellCept in Myasthenia Gravis

Oct 11, 2006

Aspreva to Release 2006 Third Quarter Results on November 1st

Sep 29, 2006

Aspreva Announces Achievement of Targeted Patient Enrolment in Phase III Clinical Trial for CellCept in Lupus Nephritis

Sep 18, 2006

Aspreva Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York

Sep 13, 2006

Aspreva Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London, England

Jul 26, 2006

Aspreva Pharmaceuticals Reports Second Quarter 2006 Results

Jul 19, 2006

Mycophenolate Mofetil Approved for Treatment of Lupus Nephritis in Malaysia

Jul 10, 2006

Aspreva Announces Preliminary Revenues for Second Quarter 2006

Jul 10, 2006

Aspreva Announces Appointment of Dr. Richard Jones as SVP Clinical and Regulatory Affairs on Planned Retirement of Dr. Reinhard Baildon

Jul 07, 2006

Aspreva to Release 2006 Second Quarter Results on July 26th

Jun 13, 2006

Aspreva Pharmaceuticals Appoints William L. Hunter, CEO of Angiotech Pharmaceuticals, to its Board of Directors

Jun 06, 2006

Aspreva and Roche Receive Orphan Drug Designation from FDA for Evaluation of CellCept in Rare Autoimmune Disease Pemphigus Vulgaris

May 22, 2006

Aspreva Pharmaceuticals Added to the NASDAQ Biotechnology Index®

May 09, 2006

Aspreva Pharmaceuticals to Present at the Banc of America Health Care Conference in Las Vegas

Apr 26, 2006

Aspreva Pharmaceuticals Reports First Quarter 2006 Results

Apr 13, 2006

Aspreva Announces Preliminary Revenues

Apr 12, 2006

Aspreva to Release 2006 First Quarter Results on April 26th

Mar 30, 2006

Aspreva Announces Completion of Patient Enrolment in Phase III Clinical Trial for CellCept in Pemphigus Vulgaris

Mar 27, 2006

Aspreva Pharmaceuticals to Present at the Windhover Pharmaceutical Strategic Outlook Conference

Feb 08, 2006

Aspreva Pharmaceuticals Reports 2005 Fourth Quarter and Year End Results

Feb 06, 2006

Aspreva Pharmaceuticals to Present at the CIBC World Markets Institutional Investor Conference in Whistler

Feb 02, 2006

Aspreva Announces Preliminary Revenues for Fourth Quarter and Fiscal Year 2005

Jan 30, 2006

Aspreva Pharmaceuticals to Present at the Merrill Lynch Global Pharma Conference

Jan 25, 2006

Aspreva to Release 2005 Fourth Quarter and Year End Results on February 8th

Jan 09, 2006

Aspreva Pharmaceuticals to Present at JP Morgan Healthcare Conference in San Francisco

Jan 03, 2006

Aspreva and Roche Receive Orphan Drug Designation From FDA For Evaluation of CellCept in Myasthenia Gravis